Key findings
Pharma companies are taking steps to address access in low-income countries, but significant gaps remain
19 November 2024
The Access to Medicine Foundation joins the World EPA Congress 2025
The Access to Medicine Foundation will participate in the World Evidence, Pricing, and Access (EPA) Congress Europe 2025, taking place in Amsterdam. Throughout the event, the Foundation will engage with leading pharmaceutical companies and industry representatives to address critical challenges in ensuring access to medicines.
Date
05 March 2025
Location
Amsterdam, Netherlands
The World Evidence, Pricing and Access (EPA) Congress is Europe’s largest event focused on market access, pricing, and evidence, bringing together over 1,500 industry leaders, policymakers, and experts. With 300 speakers and eight dedicated tracks, the Congress serves as a key forum for discussions on reimbursement models, affordability, and healthcare innovation. The Access to Medicine Foundation team will participate in the 2025 edition in Amsterdam, engaging with key stakeholders and industry representatives to advance conversations on healthcare access and pharmaceutical accountability.
In addition to attending the Congress, Jayasree K. Iyer, CEO of the Foundation, will also serve as the keynote speaker. In the session, titled “Trends and Opportunities in Achieving Health Equity from the Access to Medicine Index,” Jayasree will share fresh insights on global health equity based on the findings of the 2024 Access to Medicine Index. Launched in November 2024, the Index ranks 20 of the world’s largest pharmaceutical companies on their efforts to improve access to essential medicines in low- and middle-income countries (LMICs).
Together, the Foundation’s team will lend their expertise on the role of pharmaceutical companies in advancing equitable global access to essential medicines and explore ways to improve their efforts further.
About the World EPA Congress
The 2025 edition of this event will feature more than 1,500 attendees from the pharmaceutical, biotech, and payer/HTA sectors. This year, it will introduce a dedicated Health Economics & Outcomes Research track, along with a poster area, to strengthen the academic presence and foster deeper discussions with additional insights.
